Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Follow-Up Questions
Madrigal Pharmaceuticals Inc 'in CEO'su kimdir?
Mr. Bill Sibold 2023 'den beri şirketle birlikte olan Madrigal Pharmaceuticals Inc 'in President 'ıdır.
MDGL hissesinin fiyat performansı nasıl?
MDGL 'in mevcut fiyatı $421.51 'dir, son işlem günde 0% increased etti.
Madrigal Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Madrigal Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 17 analist Madrigal Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 6 güçlü al, 13 al, 2 tut, 1 sat ve 6 güçlü sat içermektedir
